.png){kind=icon}
返回
BEAR: A Novel Virtual Screening Method Based on Large-Scale Bioactivity Data
.png){kind=icon}
PRE
AI
DOI：10.1021/acs.jcim.2c01300.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Data-driven drug discovery exploits a comprehensive set of big data to provide an efficient path for the development of new drugs. Currently, publicly available bioassay data sets provide extensive information regarding the bioactivity profiles of millions of compounds. Using these large-scale drug screening data sets, we developed a novel in silico method to virtually screen hit compounds against protein targets, named BEAR (Bioactive compound Enrichment by Assay Repositioning). The underlying idea of BEAR is to reuse bioassay data for predicting hit compounds for targets other than their originally intended purposes, i.e., assay repositioning. The BEAR approach differs from conventional virtual screening methods in that (1) it relies solely on bioactivity data and requires no physicochemical features of either the target or ligand. (2) Accordingly, structurally diverse candidates are predicted, allowing for scaffold hopping. (3) BEAR shows stable performance across diverse target classes, suggesting its general applicability. Large-scale cross-validation of more than a thousand targets showed that BEAR accurately predicted known ligands (median area under the curve = 0.87), proving that BEAR maintained a robust performance even in the validation set with additional constraints. In addition, a comparative analysis demonstrated that BEAR outperformed other machine learning models, including a recent deep learning model for ABC transporter family targets. We predicted P-gp and BCRP dual inhibitors using the BEAR approach and validated the predicted candidates using in vitro assays. The intracellular accumulation effects of mitoxantrone, a well-known P-gp/BCRP dual substrate for cancer treatment, confirmed nine out of 72 dual inhibitor candidates preselected by primary cytotoxicity screening. Consequently, these nine hits are novel and potent dual inhibitors for both P-gp and BCRP, solely predicted by bioactivity profiles without relying on any structural information of targets or ligands.
Keyword:
DRUG
IDENTIFICATION
DISCOVERY
CHEMBL
TOOL
期刊
IF:
5.3
论文数:
9.1K
被引数:
4.0W
机构
引用论文
分享收藏ChEMBL: towards direct deposition of bioassay dataChEMBL: 走向生物测定数据的直接沉积.png)
NUCLEIC ACIDS RESEARCH
OAAI
NUCLEIC ACIDS RESEARCHIF13.1
OAAI分享收藏Machine-learning scoring functions for structure-based drug lead optimization基于结构的药物线索优化的机器学习评分函数OAAI
OAAI分享收藏KEGG: new perspectives on genomes, pathways, diseases and drugsKEGG: 基因组，途径，疾病和药物的新观点NUCLEIC ACIDS RESEARCHOAAI
NUCLEIC ACIDS RESEARCHIF13.1
OAAI分享收藏Weight status misperceptions among UK adults: the use of self-reported vs. measured BMIBMC Obesity
OAAI
BMC ObesityIF0
OAAI分享收藏
查看更多内容